Kairos Pharma, Ltd. (KAPA:NYSEMKT) closed at $0.559 on October 23, 2026, up 2.67% on the day. The stock trades 93.1% below its 52-week high of $8.12 and 7.0% above its 52-week low of $0.522. Over the past year, it lost 48.8%. Kairos Pharma, Ltd. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, KAPA closed higher on 103 days (41%). Its best day was March 9, 2026 (+601.11%) and its worst was October 6, 2026 (-25.81%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 3 times.
Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviros advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies.
Find more stocks like KAPA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.